The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Were Hedge Funds Right About Harpoon Therapeutics, Inc. (HARP)? insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Were Hedge Funds Right About NGM Biopharmaceuticals, Inc. (NGM)?
In this article we will analyze whether NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best ideas. While not all of these picks will be winners, our research shows that these picks historically outperformed the market by double digits annually.
Is
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) a superb investment today? The smart money was taking an optimistic view. The number of bullish hedge fund bets rose by 5 in recent months. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) was in 18 hedge funds’ portfolios at the end of the first quarter of 2021. The all time high for this statistic was previously 13. This means the bullish number of hedge fund positions in th
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As a result, the relevancy of these public filings and their content is indisputable, as they may reveal numerous high-potential stocks. The following article will discuss the smart money sentiment towards AnaptysBio, Inc. (NASDAQ:ANAB).